Zealand Pharma A/S, a biotechnology company, is engaged in the discovery, design and development of peptide-based medicines in Denmark. It has a drug portfolio that focuses on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical need. The company markets lixisenatide under the brand names Adlyxin, Lyxumia, Soliqua 100/33 and Suliqua. Its product line includes the Dasiglucagon single-use syringe or autoinjector that has completed phase III clinical trials for the treatment of severe hypoglycemia; The dual-hormone artificial pancreas Dasiglucagon has completed phase II clinical trials for automated diabetes management; Dasiglucagon which is in phase III clinical trials for congenital hyperinsulinism and in phase II clinical trials for bariatric postoperative hypoglycemia. The company is also developing glepaglutide, a long-acting GLP-2 analog, which is in phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. which is in phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. which is in phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.
How To Buy Zelandia Pharma A/S Stock (zeal.co) Tutorial Explained
Do you want to acquire shares of Zelandia Pharma A / S (zeal.co) in Copenhagen safely and through a regulated and quality broker? Does it surprise you to be able to monetize your earnings for the month and have profits on the stock market? In this tutorial I will show you how you can register a debit account , a reliable German investment bank and low commissions, and how you will be able to get your first share in Zelandia Pharma A / S (ZEAL.CO) (zeal .co) quickly and easily.
What we will do is easy to do :
- To start we are going to register in Degiro, an investment platform where we will buy shares of the company Zelandia Pharma A / S (ZEAL.CO) with the ticker (zeal.co).
- In this step we will add capital to then execute the first investment.
- When we see the funds, what we are going to do is look for Zelandia Pharma A / S with the ticker, which is zeal.co.
- Finally we will have to indicate the number of shares that we want, the value and the type of order.
Maybe this step by step has been a bit essential for you, so I am going to summarize the step by step with images.
How to open an account with DEGIRO.
The first step is to register in degiro from the following link :
It will ask us for an email, a username and a pin code to have access, and later we will have to continue with the link that they have sent us by email address.
Soon Degiro is going to ask us for information of interest with which they are going to approve our identity card . We will need to have our passport, ID or driver’s license, our telephone number and the number of the bank account that we will use to make our 1st deposit. If you don’t know how this format works, you can check this simple guide article that we developed at Educaceps.es .
Once our account has been validated, we will have to pay money from the Deposit/Withdraw tab. We will be able to carry out a transaction that will take between 1-3 days, or make the deposit instantly thanks to Sofort, a 100% secure and 100% reliable payment gateway.
How to buy Zelandia Pharma A/S (zeal.co) shares via Degiro
In the time that we have the money we have the possibility of buying our 1st share. You can use the place order button in the upper right corner or use the DEGIRO search engine and type the ticker. In the following image you will see that I have put the Amazon ticker but you must enter (zeal.co), the Zelandia Pharma A / S ticker. As we are talking about an action, we will see that the related results are listed and there we will look in finding Zelandia Pharma A / S. The most important thing is that the ticker, the name of the share and the market in which it is listed coincide. Amazon is listed on Nasdaq (NDQ) and in your case Zelandia Pharma A/S (ZEAL.CO) is listed in Copenhagen. This step is important so don’t get confused.
At the moment of carrying out the order, we must pay special attention to what is next . We will have the possibility of placing a limit or market order. Imagine that you plan to purchase a share of Zelandia Pharma A/S, but its real price is too prominent. With the limit order we will enter the value at which we want to make the acquisition and until there are no shares selling at a certain value, the purchase of the share will not be executed. With a market order DeGiro will buy the number of shares we have added to the actual selling price, which will be very close to the live trading price.
In all cases it is very convenient that you look at the type of numbering: fixed or of the day . For example, in Spain, the stock market listing is in the morning until 1 in the afternoon, and in the US it corresponds to the afternoon schedule in Spain. If an order is fixed, it will continue until the point where it manages to be executed, but if you select the «of the day» option, at the end of the day, if it had not been carried out, it will be removed from your Activity tab – Orders in process.
I would love that this quick post has helped you to invest in Zelandia Pharma A / S. Until next time.
|Name||Title||Salary||exercised||Year of birth|
|Dr. Emmanuel Dulac Pharm.D., PharmD, Ph.D., MBA||CEO and president||12.44 million||N/A||1969|
|Mr Matthew Donald Dallas||Senior Vice President and Chief Financial Officer||5.67 million||N/A||1975|
|Ms. Hanne Heidenheim Bak||Senior Project Manager, R&D Operations Mang. and Employee Representative Director||133k||N/A||1953|
|Mr. Adam Sinding Steensberg MD||Exec. Vice President of R&D and Medical Director||7.39 million||N/A||1974|
|Mr. Ivan Mourits MÃ¸ller||Senior Vice President of Technical Development. and operations||N/A||N/A||1972|
|Mrs. Rie Schultz Hansen||Vice President of Discovery and Innovation||N/A||N/A||N/A|
|Lani Pollworth Morvan||Head of Communications and Investor Relations||N/A||N/A||N/A|
|Mr Mads Kronborg||Head of Investor Relations and Communication||N/A||N/A||N/A|
|Søren Vitfell Keller||Head of Legal Affairs||N/A||N/A||N/A|
|Mr. Marino Garcia MBA||Senior Vice President of Corp. Bus. Devel.||N/A||N/A||1966|
Recent events of :
We have no recent events for this company.